M3, Inc. (MTHRY)
OTCMKTS · Delayed Price · Currency is USD
7.96
+0.07 (0.89%)
Sep 12, 2025, 3:58 PM EDT
M3, Inc. Revenue
M3, Inc. had revenue of 86.20B JPY in the quarter ending June 30, 2025, with 34.25% growth. This brings the company's revenue in the last twelve months to 306.89B, up 24.91% year-over-year. In the fiscal year ending March 31, 2025, M3, Inc. had annual revenue of 284.90B with 19.26% growth.
Revenue (ttm)
306.89B JPY
Revenue Growth
+24.91%
P/S Ratio
5.11
Revenue / Employee
19.98M JPY
Employees
15,360
Market Cap
10.87B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 284.90B | 46.02B | 19.26% |
Mar 31, 2024 | 238.88B | 8.07B | 3.49% |
Mar 31, 2023 | 230.82B | 22.66B | 10.89% |
Mar 31, 2022 | 208.16B | 38.96B | 23.03% |
Mar 31, 2021 | 169.20B | 38.23B | 29.19% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
M3, Inc. News
- 4 years ago - M3, Inc.: Stand-Out Success Story Of Japanese Internet - Seeking Alpha
- 4 years ago - 5 Health Care Stocks Growing Fast - GuruFocus
- 5 years ago - 5 Telehealth Stocks for Long-Term Financial Fitness - Kiplinger